Yuangang Su

690 total citations
40 papers, 517 citations indexed

About

Yuangang Su is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yuangang Su has authored 40 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 20 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Yuangang Su's work include Bone Metabolism and Diseases (32 papers), Bone health and treatments (18 papers) and NF-κB Signaling Pathways (7 papers). Yuangang Su is often cited by papers focused on Bone Metabolism and Diseases (32 papers), Bone health and treatments (18 papers) and NF-κB Signaling Pathways (7 papers). Yuangang Su collaborates with scholars based in China, Australia and United States. Yuangang Su's co-authors include Jinmin Zhao, Jiake Xu, Jiamin Liang, Qian Liu, Fangming Song, Junchun Chen, Dezhi Song, Xixi Lin, Ziyi Wang and Yu Xiao and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Free Radical Biology and Medicine and Biochemical Pharmacology.

In The Last Decade

Yuangang Su

37 papers receiving 517 citations

Peers

Countries citing papers authored by Yuangang Su

Since Specialization

Citations

This map shows the geographic impact of Yuangang Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuangang Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuangang Su more than expected).

Fields of papers citing papers by Yuangang Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuangang Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuangang Su. The network helps show where Yuangang Su may publish in the future.

Co-authorship network of co-authors of Yuangang Su

This figure shows the co-authorship network connecting the top 25 collaborators of Yuangang Su. A scholar is included among the top collaborators of Yuangang Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuangang Su. Yuangang Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Farrerol alleviates microbiota dysbiosis-associated osteoporosis in IBD by inhibiting PI3K-AKT/MAPK signaling pathways 2025 ·Phytomedicine ·Ning Yin, Yuangang Su, Chaofeng Wang, Jiamin Liang, (unknown), (unknown), Zemin Ling, Ren Xu, Qian Liu	1
2	Brevilin A, a novel BNIP3 inhibitor suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss via impairing mitophagy and mitochondrial metabolism 2025 ·Phytomedicine ·(unknown), Yiyuan Wang, (unknown), Yuangang Su, (unknown), (unknown), (unknown), (unknown), Jiake Xu, Qian Liu, Fangming Song	0
3	Rc3h1 negatively regulates osteoclastogenesis by limiting energy metabolism 2024 ·Theranostics ·(unknown), Yuangang Su, Chaofeng Wang, (unknown), Weiwei Chen, (unknown), (unknown), Hao‐Yu Lian, Jinmin Zhao, Jiake Xu, Qian Liu	3
4	Regorafenib Attenuates Osteoclasts Differentiation by Inhibiting the NF-κB, NFAT, ERK, and p38 Signaling Pathways 2024 ·ACS Omega ·(unknown), (unknown), (unknown), (unknown), Qian Liu, Yuangang Su, (unknown), (unknown)	2
5	Hecogenin alleviates LPS-induced osteolysis via regulating pyroptosis and ROS involved Nrf2 activation 2024 ·Biomedicine & Pharmacotherapy ·Zhijuan Liu, Yijie Gao, (unknown), Yuangang Su, (unknown), (unknown), Jiake Xu, (unknown), (unknown)	3
6	Active fraction of Polyrhachis vicina (Rogers) inhibits osteoclastogenesis by targeting Trim38 mediated proteasomal degradation of TRAF6 2024 ·Phytomedicine ·(unknown), Guining Wei, Yuangang Su, (unknown), (unknown), (unknown), Jiamin Liang, (unknown), Jiake Xu, Jinmin Zhao, Qian Liu, Fangming Song	3
7	IKK/NF‐κB and ROS signal axes are involved in Tenacissoside H mediated inhibitory effects on LPS‐induced inflammatory osteolysis 2023 ·Cell Proliferation ·(unknown), Weiwei Chen, (unknown), Junchun Chen, (unknown), Chaofeng Wang, Yuangang Su, Jinmin Zhao, Jiake Xu, Qian Liu	14
8	Ethyl caffeate inhibits macrophage polarization via SIRT1/NF-κB to attenuate traumatic heterotopic ossification in mice 2023 ·Biomedicine & Pharmacotherapy ·Hui Wang, Dezhi Song, (unknown), (unknown), (unknown), Yuangang Su, Jiamin Liang, Hao‐Yu Lian, (unknown), Qian Liu	8
9	Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL‐induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation 2023 ·Free Radical Biology and Medicine ·(unknown), Dezhi Song, Xixi Lin, Hui Peng, Yuangang Su, Jiamin Liang, (unknown), (unknown), Qian Liu	15
10	Casticin suppresses RANKL‑induced osteoclastogenesis and prevents ovariectomy‑induced bone loss by regulating the AKT/ERK and NF‑κB signaling pathways 2023 ·International Journal of Molecular Medicine ·Fan Yang, Yuangang Su, Jiamin Liang, Keyi Wang, (unknown), Junchun Chen, Jiake Xu, (unknown), Qian Liu	6
11	Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-κB/MAPK signaling pathways 2023 ·Biomedicine & Pharmacotherapy ·(unknown), Dezhi Song, Shijie Liao, Junchun Chen, (unknown), Yuangang Su, (unknown), Hui Peng, (unknown), Kai Chen, Jiake Xu, Jinmin Zhao, (unknown)	19
12	Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced Osteolysis 2022 ·Frontiers in Pharmacology ·(unknown), Weiwei Chen, (unknown), Yuangang Su, Jiamin Liang, (unknown), Hui Wang, (unknown), Fan Yang, (unknown), Zhen Tan, Jiake Xu, Jinmin Zhao, Qian Liu	9
13	Comparisons of Forecasting for Survival Outcome for Head and NeckSquamous Cell Carcinoma by using Machine Learning Models based onMulti-omics 2022 ·Current Genomics ·Daizheng Huang, (unknown), Yuangang Su, Jianhui Yuan, (unknown), Ziyan Zhang, (unknown)	3
14	Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway 2022 ·European Journal of Pharmacology ·Liwei Wu, Jiamin Liang, Jing Li, Yang Xu, Junchun Chen, Yuangang Su, (unknown), (unknown), Jiake Xu, Jinmin Zhao, Qian Liu, Yuan Yang	5
15	AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosis 2022 ·International Immunopharmacology ·(unknown), Dezhi Song, Ziyi Wang, Yuangang Su, Junchun Chen, (unknown), Jian Huang, Jing Li, Jiake Xu, Jinmin Zhao, Qian Liu	12
16	Anti-Osteoclast Effect of Exportin-1 Inhibitor Eltanexor on Osteoporosis Depends on Nuclear Accumulation of IκBα–NF-κB p65 Complex 2022 ·Frontiers in Pharmacology ·Junchun Chen, Dezhi Song, Yang Xu, Liwei Wu, Lili Tang, Yuangang Su, (unknown), Jinmin Zhao, Jiake Xu, Qian Liu	5
17	Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways 2021 ·Frontiers in Pharmacology ·Xue Yang, Jiamin Liang, Ziyi Wang, Yuangang Su, (unknown), (unknown), Jing Li, Xuedong Li, (unknown), Jinmin Zhao, Jiake Xu, Qian Liu, Bo Zhou	28
18	Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways 2021 ·Drug Design Development and Therapy ·Xuedong Li, Xixi Lin, (unknown), Yuangang Su, Jiamin Liang, Runfeng Chen, Xue Yang, Lei Hou, Jinmin Zhao, Qian Liu, Xu Feng	9
19	Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation 2021 ·Biochemical Pharmacology ·(unknown), Yuangang Su, Jiamin Liang, Feng Long, (unknown), Yu Xiao, (unknown), Jiake Xu, Jinmin Zhao, Qian Liu, Fangming Song	67
20	Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice 2020 ·Frontiers in Pharmacology ·(unknown), Jiamin Liang, Kun Tian, Zhigang Che, Ziyi Wang, Xue Yang, Yuangang Su, Xixi Lin, Fangming Song, Jinmin Zhao, Jiake Xu, Qian Liu, Bo Zhou	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoon‐Hee Cheon Breakdown of academic impact, for papers by Yonghui Dong Breakdown of academic impact, for papers by Zhiping Miao Breakdown of academic impact, for papers by Jyoti Kureel Breakdown of academic impact, for papers by Nianhu Li Breakdown of academic impact, for papers by Jiachen Lin Breakdown of academic impact, for papers by S.H. Madsen Breakdown of academic impact, for papers by Jinti Lin